USPTO Patent Application: Thiazolidine Linkers for Protein-Drug Conjugates

ChangeBridge: Patent Apps - Peptides (C07K)

Published September 11th, 2025

Detected March 26th, 2026

Summary

The USPTO has published a new patent application (US20260083856A1) detailing thiazolidine linkers for protein-drug conjugates and their uses in treating diseases. The application was filed on September 11, 2025, and is scheduled for publication on March 26, 2026.

View original document View source feed page

What changed

This document is a publication of a United States patent application, specifically US20260083856A1, filed on September 11, 2025. The application describes novel thiazolidine (Tz) linkers designed for creating protein-drug conjugates, along with methods for their production and their application in treating diseases or disorders.

As this is a patent application, it does not impose immediate regulatory obligations on companies. However, it signals potential future intellectual property developments in the field of protein-drug conjugates. Companies involved in drug development, particularly those working with antibody-drug conjugates or similar targeted therapies, should monitor this application and related patents for potential licensing opportunities or competitive landscape shifts.

Source document (simplified)

← USPTO Patent Applications

THIAZOLIDINE LINKERS FOR PROTEIN-DRUG CONJUGATES AND USES THEREOF

Application US20260083856A1 Kind: A1 Mar 26, 2026

Inventors

Xiao Cai, Stepan Chuprakov, Reji Nair, Ayodele Ogunkoya, Matthew Smith

Abstract

The present disclosure provides thiazolidine (Tz) linkers for protein-drug conjugates. In addition, the disclosure also encompasses compounds useful for producing such protein-drug conjugates, as well as methods for production of such protein-drug conjugates. The disclosure also encompasses methods of using the protein-drug conjugates for the treatment of a disease or disorder in a subject.